Eye2Gene: using AI to speed up diagnosis for inherited eye diseases
Giving patients answers about their sight loss in weeks, not years.
Inherited retinal diseases (IRDs) can cause severe vision loss or even blindness, and affect millions globally. For most of these diseases, there are no effective treatments.
IRDs are an incredibly diverse group of conditions, linked to more than 400 genes, including two common instances:
- Retinitis Pigmentosa (RP), which typically begins with night blindness followed by the loss of peripheral vision,
- Stargardt Disease, a form of inherited macular dystrophy that commonly affects central vision.
Problem to be solved
Despite significant improvements in genomic medicine, diagnosing an IRD is difficult, even for the most knowledgeable of clinicians, as most belong to the rare eye disease category (fewer than 200,000 people are affected).
Different mutations in the same gene can cause wildly varying symptoms, but symptoms can also overlap from one condition to another, appearing visually similar in imaging.
Given this complexity, patients can wait on average 6.4 years to understand the condition they have and often face barriers accessing specialised genetic testing – all while their sight continues to worsen, with no plan or understanding of the prognosis and what might come next.
Solution
Eye2Gene applies AI to retinal scans to enable a higher level of precision analysis than traditional methods. The platform – based on research from the UCL Institute of Ophthalmology – then generates a list of likely genes involved, ranked by their likelihood, and helps clinicians prioritise genetic testing.
By supporting clinicians’ existing expertise, the spinout’s technology helps to confirm the mechanisms, or process, of the disease and identify the mutation that caused the IRD.
This means an accelerated diagnosis process for patients, receiving answers in weeks, rather than years. Timely diagnosis can prevent further vision loss through earlier interventions, where they are available, and lead to improved long-term outcomes.
How UCL Ventures helped
UCL Ventures partnered with Dr Nikolas Pontikos and Professor Michel Michaelides to explore the commercial potential of the technology and identify the best route to take it forward.
The team assessed the clinical opportunity and helped shape how the technology could be positioned, including building the evidence around its potential to scale within the clinical trials environment. This work helped establish the case for creating a spinout company.
Alongside managing the intellectual property, UCL Ventures supported the team in navigating the regulatory considerations around the use of AI and the products and services the new company could offer.
The support did not stop at the point of spinning out: we helped with introductions to the investor world, including at both 2025 and 2026 London Life Sciences Week, where Eye2Gene pitched their technology to a room of investors.
Team
Dr Nikolas Pontikos
Co-founder and CEO
Associate Professor at the Institute of Ophthalmology, working at intersection of genetics, imaging and text data to develop decision support systems for precision diagnosis, prognosis and treatment.
Dr. Mark Fisher
Associate Director
Dr Fisher has management responsibility for the BioPharm patent portfolio and strategic business support for the BioPharm team. At the coalface, Mark manages the commercialisation of technology from
the Institute of Ophthalmology and Moorfields Eye Hospital UCL Global Business School for Health and the Department of Ageing, Arthritis and Regenerative Medicine.
He holds a first degree in Industrial Biology and a PhD in Biochemistry and Molecular Biology from UCL, in association with one of the first biotechnology companies to be established in the academic sector.
Mark brings more than 30 years of experience in life sciences and healthcare licensing, new company development and securing investment from both the public and private sectors to his team. To date, Mark has been responsible for the establishment of more than 25 new businesses in diagnostics, drug discovery, medical devices and therapeutics.
As a certified lead auditor of ISO 13485, Dr Fisher has additional experience in quality management systems and the translation of technologies from research and design into manufacture at home and abroad.
Mark is a Freeman of the Worshipful Company of Management Consultants and gained the Freedom of the City of London in 2010 for his contribution to the economy through new business development.